NAMS
NewAmsterdam Pharma Company N.V (NAMS) Investor Questions
Review NewAmsterdam Pharma Company N.V (NAMS) faq with company data, supporting context and links to related investor research.
Research record updated: . Individual measures may refer to different reporting periods.
- Company
- NewAmsterdam Pharma Company N.V
- Sector
- Healthcare
- Industry
- Biotechnology
- Overall BTI score
- 60
- Annual revenue
- $22.50M
- Annual net income
- $-203.82M
- Annual free cash flow
- $-148.03M
NewAmsterdam Pharma Company N.V (NAMS) Investor Questions research
NewAmsterdam Pharma Company N.V trades under the ticker NAMS. The company is classified in the Healthcare sector and the Biotechnology industry.
Investors commonly review NAMS through its earnings trend, revenue, free cash flow, balance sheet, valuation and historical risk. Use the financial statements to check whether reported profit is supported by cash generation.